Providing market intelligence for more than 35 years

In The News

No, Apple's licensing of iTunes & AirPlay 2 isn't a 'strategy reversal' in any way

That claim cited research by Parks Associates, which actually showed that Apple TV's share by installed base was not drying up and blowing away as Mims portrayed, but was actually better than Google's and far ahead of Sony or Tivo.

It also stated that consumers rated Apple TV highly in setup, usability, gaming, and for purchasing content. It also noted that almost half of smart TV owners also used a streaming media player and that they used their media player much more frequently than their TV's built-in services. Yet Mims was so desperate to take swipes at Apple that he fudged the findings of that research. None of those facts fit his narrative of the "failing Apple TV that nobody uses," so he left them out.  

From the article "No, Apple's licensing of iTunes & AirPlay 2 isn't a 'strategy reversal' in any way" by Daniel Erin Dilger.

Previously In The News

Parks: US Churn Rate For OTT Services Is 19%

This is according to Parks Associates’ latest ‘OTT Video Market Tracker’ stats, which said that overall churn rate for OTT services has been roughly stable for the past year. At the end of 2015, 20...

One in five US subscribers now ‘dissatisfied’ with pay TV service

Some 20% of US pay TV subscribers are now dissatisfied with their pay TV service, according to research from Parks Associates. The future represents a 100% increase since 2013, according to Parks....

Over Two-Thirds Of U.S. Smartphone Owners Stream Music Daily

A recent Parks Associates report reveals that 68 percent of U.S. smartphone owners listen to streaming music every day, for an average of 45 minutes per day. Amazon Prime Music emerged as the most pop...

Morning Read: Pharma Changes Afoot As Valeant Courts A New CEO And Novartis U.S. Head Exits

Less than half of caregivers with a smartphone use apps aimed at caregivers, according to a report by Parks Associates. — MobiHealthNews From the article "Morning Read: Pharma Changes Afoot As Vale...